Introduction and hypothesis
To determine prevalence and quality of life impact of lower urinary tract symptoms (LUTS) in women living with HIV (WLWH).
Cross-sectional urinary questionnaires were included in a multicenter national prospective study of the HPV vaccine in WLWH. Demographic and clinical information was abstracted from the parent study. The Urinary Distress Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7) were administered. Wilcoxon rank sum, two-sample chi-square or Fisher’s exact tests were used as appropriate to compare women with UDI-6 score ≥ 25 to those with lower UDI-6 scores on demographic and HIV-related factors. Significant categorical variables were followed up with logistic regression to estimate odds ratios (OR).
One hundred seventy-seven women completed urinary questionnaires (85.5% of cohort). Median age was 44.1 (37.2–50.6). Mean CD4 count was 621 (410–785), and 132 women (74.6%) were virologically suppressed. Median UDI-6 score was 4.2 (0–25). Fifty-one women (28.8%) had a UIQ-7 score > 0. Among those with a UDI-6 score of at least 25, median UIQ-7 was 9.5 (0–47.6). UDI-6 ≥ 25 was significantly associated with increasing age, higher BMI, Canada as country of origin, peri-/postmenopausal status (OR 3.37, 95% CI = 1.71 to 6.75) and being parous (OR 2.92, 95% CI = 1.27 to 7.59) (all p < 0.05). HIV-related factors were not associated with UDI-6 ≥ 25.
LUTS were common, but we did not demonstrate a negative impact on quality of life in this sample of WLWH. Large comparative studies are needed to determine whether HIV is a risk factor for bothersome LUTS in women.
This is a preview of subscription content,to check access.
Access this article
Acquired immunodeficiency syndrome
Human Immunodeficiency Syndrome
Lower urinary tract symptoms
Urinary Distress Inventory
Urinary Impact Questionnaire
Women living with HIV
Cooper J, Annappa M, Quigley A, Dracocardos D, Bondili A, Mallen C (2014) Prevalence of female urinary incontinence and its impact on quality of life in a cluster population in the United Kingdom (UK): a community survey. Prim Health Care Res Dev 1–6. https://doi.org/10.1017/S1463423614000371.
Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352–60. https://doi.org/10.1111/j.1464-410X.2009.08427.x.
Caruso S, Brescia R, Matarazzo MG, Giunta G, Rapisarda AMC, Cianci A. Effects of urinary incontinence subtypes on Women's sexual function and quality of life. Urology. 2017;108:59–64. https://doi.org/10.1016/j.urology.2017.06.025.
Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(Suppl 3):4–11. https://doi.org/10.1111/j.1464-410X.2009.08371.x.
Handa VL, Harvey L, Fox HE, Kjerulff KH. Parity and route of delivery: does cesarean delivery reduce bladder symptoms later in life? Am J Obstet Gynecol. 2004;191(2):463–9. https://doi.org/10.1016/j.ajog.2004.03.031.
Kim JH, Sun HY, Park SY, Soh MJ, Kim YJ, Song YS. Association between obesity and lower urinary tract symptoms: propensity score matching study between healthy controls and obese patients seeking bariatric surgery. Surg Obes Relat Dis. 2016;12(8):1585–93. https://doi.org/10.1016/j.soard.2016.04.027.
Gyrtrup HJ, Kristiansen VB, Zachariae CO, Krogsgaard K, Colstrup H, Jensen KM. Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol. 1995;29(3):295–8.
Hermieu JF, Delmas V, Boccon-Gibod L. Micturition disturbances and human immunodeficiency virus infection. J Urol. 1996;156(1):157–9.
Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119–25. https://doi.org/10.7326/0003-4819-127-2-199707150-00004.
Skrzat-Klapaczyńska A, Matłosz B, Bednarska A, Paciorek M, Firląg-Burkacka E, Horban A, et al. Factors associated with urinary tract infections among HIV-1 infected patients. PLoS One. 2018;13(1):e0190564. https://doi.org/10.1371/journal.pone.0190564.
McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N, et al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus. Clin Infect Dis. 2019;68(5):788–94. https://doi.org/10.1093/cid/ciy575.
Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34(40):4799–806. https://doi.org/10.1016/j.vaccine.2016.08.016.
Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol. 2005;193(1):103–13. https://doi.org/10.1016/j.ajog.2004.12.025.
Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1–12.
Gafni-Kane A, Zhou Y, Botros SM. Predictive modeling and threshold scores for care seeking among women with urinary incontinence: the short forms of the pelvic floor distress inventory and urogenital distress inventory. Neurourol Urodyn. 2015. https://doi.org/10.1002/nau.22833.
Breyer BN, Van den Eeden SK, Horberg MA, Eisenberg ML, Deng DY, Smith JF, et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol. 2011;185(5):1710–5. https://doi.org/10.1016/j.juro.2010.12.043.
Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, et al. Geriatric syndromes in older HIV-infected adults. J Acquir Immune Defic Syndr. 2015;69(2):161–7. https://doi.org/10.1097/QAI.0000000000000556.
Valadares AL, Pinto-Neto AM, Gomes DC, D'Avanzo WC, Moura AS, Costa-Paiva L, et al. Dyspareunia in HIV-positive and HIV-negative middle-aged women: a cross-sectional study. BMJ Open. 2014;4(11):e004974. https://doi.org/10.1136/bmjopen-2014-004974.
Shindel AW, Akhavan A, Sharlip ID. Urologic aspects of HIV infection. Med Clin North Am. 2011;95(1):129–51. https://doi.org/10.1016/j.mcna.2010.08.017.
Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300(11):1311–6. https://doi.org/10.1001/jama.300.11.1311.
Work was supported by the Canadian Institutes for Health Research (CIHR) (funding reference number: MOP 136784); CIHR Canadian HIV Trials Network (CTN 236); Reseau FRSQ SIDA-MI supported quality control of the linear array; Chair in Biostatistics from the Ontario HIV Treatment Network to J.R.; and in-kind contribution of vaccine and HPV antibody analysis from Merck Canada Inc. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Canada Inc. We would also like to acknowledge Sandra Blitz and Janet Raboud for doing the initial statistical analysis for the poster presentation of this project as well as Drs. Jorge Martinez-Cajas, Wendy Wobeser, Sarah Stone, Jeff Cohen and Marina Klein for helping to recruit participants for this project. Finally, this project was made possible by the HPV in HIV study group.
A Albert, N Lipsky and Dr. DM Money report research grants from the Canadian Institutes for Health Research (CIHR). Dr. GW Cundiff is the immediate past president of the Americal Urogynecologic Society. Dr. S Trottier reports grants from GSK, Merck, ViiV, AbbVie, Janssen, Amgen and Pfizer outside of the submitted work. Dr. S Walmsley reports serving on advisory boards, lectures, meetings, symposiums and clinical trials with GSK, ViiV, Merck, Gilead and Janssen. Merck provided HPV vaccines in kind, and HPV serologies were conducted in their laboratories at no cost for the parent study, but this was an investigator driven protocol. Drs. A Bitnun, M Larouche, M Loutfy, F Smaill and MH Yudin have nothing to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Institution where work was performed
Multicenter Canadian Study with the principal investigator (Dr. Deborah Money) based in Vancouver (BC). Other study sites included Toronto (ON), Hamilton (ON), Kingston (ON), Ottawa (ON), Windsor (ON), Montreal (QC) and Quebec (QC)
Appendix I: HIV-related conditions
Appendix I: HIV-related conditions
Persistent generalized lymphadenopathy > 1 month
Fever > 38.5ºC or 101.3ºF, otherwise undiagnosed
Idiopathic thrombocytopenic purpura (ITP)
Oral thrush (candida infection)
Oral hairy leukoplakia
Shingles (herpes zoster)
Diarrhea (otherwise undiagnosed) > 1 month
Cryptosporidiosis (with diarrhea)
Peripheral neuropathy (not drug related)
Peripheral neuropathy (unknown)
Cervical dysplasia or cervical intraepithelial neoplasia
Candida (yeast) vaginitis - persistent
Pelvic inflammatory disease (PID)
Lymphocytic interstitial pneumonitis (LIP)
About this article
Cite this article
Larouche, M., Albert, A.Y.K., Lipsky, N. et al. Urinary symptoms and quality of life in women living with HIV: a cross-sectional study. Int Urogynecol J 32, 353–358 (2021). https://doi.org/10.1007/s00192-020-04343-z